Protocol Ledger

NCT04626596 · Phase III · COMPLETED

A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)

Interventional Phase III clinical trial protocol NCT04626596 sponsored by Organon and in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-19 Enrollment: 498 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04626596
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)498 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04626596
Protocol FieldVerified Registry Value
NCT IdentifierNCT04626596
Consolidated Lead SponsorOrganon and
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment498 participants (ACTUAL)
Registered Start Date2020-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI